Dermatophytic Onychomycosis Treatment Market
Dermatophytic Onychomycosis Treatment Market Forecasts to 2032 - Global Analysis By Product Type (Tablets, Nail Paints/Lacquers, Ointments & Creams, Laser Therapy Devices, Photodynamic Therapy (PDT) Solutions, and Other Product Types), Route of Administration, Treatment, Distribution Channel and By Geography
According to Stratistics MRC, the Global Dermatophytic Onychomycosis Treatment Market is accounted for $5.7 billion in 2025 and is expected to reach $10.8 billion by 2032 growing at a CAGR of 9.5% during the forecast period. The treatment of dermatophytic onychomycosis involves medical procedures designed to eradicate fungal infections that primarily affect the nails. This condition, caused by dermatophytes, results in nail thickening, discoloration, fragility, and in advanced cases, detachment. Management strategies include systemic antifungal medications like terbinafine and itraconazole, which help eliminate fungal infections internally, and topical solutions such as ciclopirox for surface application. For stubborn infections, additional therapies like laser treatment and mechanical nail removal may be used to enhance effectiveness.
According to the Centre for Disease Control and Prevention in 2022, nail fungus or dermatophytic onychomycosis affects around 26 million people in the U.S. each year.
Market Dynamics:
Driver:
Rising prevalence of fungal nail infections
The global dermatophytic onychomycosis treatment market is driven by the increasing incidence of fungal nail infections, particularly among aging populations and immunocompromised individuals. Conditions like diabetes and peripheral vascular disease heighten susceptibility to onychomycosis, fueling demand for effective treatments. Rising awareness through diagnostic campaigns and telehealth platforms has improved early detection rates. Lifestyle factors, such as prolonged use of occlusive footwear and exposure to communal spaces, further contribute to infection spread. Additionally, the growing geriatric demographic, prone to nail thickening and reduced blood flow, amplifies market growth.
Restraint:
Long treatment duration and high recurrence rates
Extended therapy periods, often spanning 6–12 months, lead to patient non-compliance and treatment abandonment. Topical solutions struggle with poor nail penetration, resulting in incomplete eradication of fungi. High recurrence rates (20–30%) due to biofilm formation and residual spores diminish patient confidence in existing therapies. The financial burden of prolonged treatment regimens, including frequent clinical visits, discourages adherence. Additionally, limited efficacy of over-the-counter products in severe cases exacerbates frustration among patients.
Opportunity:
Advancements in novel antifungal therapies
Innovations like nanoparticle-based topical formulations enhance drug delivery to the nail bed, improving efficacy and reducing treatment timelines. Development of oral antifungals with fewer hepatotoxic side effects, such as fosravuconazole, attracts patient preference. Combination therapies targeting both fungal cells and biofilms show promise in lowering recurrence rates. Partnerships between pharmaceutical firms and biotech startups accelerate R&D in gene-based and laser therapies. Regulatory approvals for novel mechanisms, such as keratin disruptors, further expand therapeutic options.
Threat:
Emergence of drug-resistant fungal strains
Overuse of conventional antifungals like terbinafine has led to resistant dermatophyte strains, complicating treatment outcomes. Limited antifungal drug pipelines compared to antibacterial research delay solutions for resistant infections. Cross-resistance mechanisms in fungi reduce the effectiveness of newly launched therapies. Diagnostic challenges in identifying resistant strains hinder targeted treatment strategies. Additionally, regulatory hurdles in approving next-generation antifungals slow market response to evolving pathogens.
Covid-19 Impact:
The pandemic disrupted routine podiatric care, delaying diagnoses and treatments for onychomycosis. Supply chain interruptions affected the availability of topical and oral antifungals, particularly in emerging markets. Increased focus on hygiene practices temporarily reduced infection rates but diverted healthcare resources away from non-urgent conditions. Post-pandemic, tele-dermatology platforms gained traction for remote consultations and prescription renewals. Recovery efforts prioritized R&D investments in home-applied therapies, aligning with patient preferences for minimal clinic visits.
The ointments & creams segment is expected to be the largest during the forecast period
The Ointments & Creams segment is expected to account for the largest market share during the forecast period ue to their widespread availability as first-line treatments and over-the-counter accessibility. Their non-invasive nature appeals to patients wary of systemic therapies or invasive procedures. Innovations in permeation enhancers, such as urea-based formulations, improve nail penetration for better efficacy. Cost-effectiveness compared to prescription drugs drives adoption in low-income regions. However, limitations in treating severe infections restrict their use to mild-to-moderate cases.
The drugs segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Drugs segment is predicted to witness the highest growth rate due to the introduction of advanced oral antifungals with shorter regimens and higher cure rates. Newer agents like VT-1161 (oteseconazole) target fungal-specific enzymes, minimizing human cell toxicity. Rising preference for systemic therapies in recalcitrant cases supports segment growth. Increased healthcare spending in emerging economies boosts access to prescription medications. Additionally, clinical trials exploring pulsed dosing regimens enhance patient compliance and outcomes.
Region with largest share:
During the forecast period, the Asia-Pacific region is expected to hold the largest market share due to high fungal infection prevalence linked to tropical climates and dense populations. Growing healthcare infrastructure in countries like India and China improves diagnostic capabilities. Rising disposable incomes enable access to premium therapies, including laser treatments. Government initiatives to combat neglected tropical diseases prioritize antifungal R&D. Cultural factors, such as barefoot practices in communal areas, also contribute to regional demand.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by advanced healthcare systems and high patient awareness of treatment options. Strong presence of key pharmaceutical players accelerates the launch of novel therapies. Insurance coverage for prescription antifungals enhances affordability and adoption. Increasing diabetic populations and obesity rates heighten susceptibility to onychomycosis. Regulatory incentives for orphan drug designations in rare fungal strains further propel market growth.
Key players in the market
Some of the key players in Dermatophytic Onychomycosis Treatment Market include Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergan, Inc., Cipla Ltd, and Medimetriks Pharmaceuticals Inc.
Key Developments:
In September 2024, Celtic Pharma announced OnychoCure, a dual-action oral + topical combo therapy targeting dermatophytes and biofilms. The regimen includes a once-weekly fluconazole tablet and a biofilm-disrupting ciclopirox spray, achieving 88% cure rates in Phase III trials.
In August 2024, Novartis AG partnered with Moberg Pharma AB to commercialize MOB-015, a patented topical amorolfine solution with microneedle-assisted application. The device ensures precise drug delivery to the nail matrix, reducing recurrence rates by 40% compared to conventional lacquers.
In July 2024, Pfizer Inc. introduced TerbinafineX, a topical nanoemulsion gel with deep nail penetration technology. The formulation uses lipid-based carriers to enhance delivery of terbinafine into the nail bed, achieving microbial eradication in 8 weeks. It is FDA-approved for diabetic patients, addressing a high-risk demographic.
Product Types Covered:
• Tablets
• Nail Paints/Lacquers
• Ointments & Creams
• Laser Therapy Devices
• Photodynamic Therapy (PDT) Solutions
• Other Product Types
Route of Administrations Covered:
• Oral
• Topical
• Other Route of Administrations
Treatments Covered:
• Drugs
• Lasers
• Photodynamic Therapy
• Other Treatments
End Users Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Dermatophytic Onychomycosis Treatment Market, By Product Type
5.1 Introduction
5.2 Tablets
5.3 Nail Paints/Lacquers
5.4 Ointments & Creams
5.5 Laser Therapy Devices
5.6 Photodynamic Therapy (PDT) Solutions
5.7 Other Product Types
6 Global Dermatophytic Onychomycosis Treatment Market, By Route of Administration
6.1 Introduction
6.2 Oral
6.3 Topical
6.4 Other Route of Administrations
7 Global Dermatophytic Onychomycosis Treatment Market, By Treatment
7.1 Introduction
7.2 Drugs
7.3 Lasers
7.4 Photodynamic Therapy
7.5 Other Treatments
8 Global Dermatophytic Onychomycosis Treatment Market, By Distribution Channel
8.1 Introduction
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies
8.5 Drug Stores
9 Global Dermatophytic Onychomycosis Treatment Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Bausch Health Companies
11.2 Galderma S.A.
11.3 Celtic Pharma
11.4 Anacor pharmaceuticals, Inc.
11.5 Johnson & Johnson
11.6 Novartis AG
11.7 Pfizer Inc.
11.8 GlaxoSmithKline
11.9 Topica Pharmaceuticals, Inc.
11.10 Moberg Pharma AB
11.11 Bayer AG
11.12 Dr. Reddy’s Laboratories Ltd
11.13 Allergen, Inc.
11.14 Cipla Ltd
11.15 Medimetriks Pharmaceuticals Inc.
List of Tables
1 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Region (2024-2032) ($MN)
2 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Product Type (2024-2032) ($MN)
3 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Tablets (2024-2032) ($MN)
4 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Nail Paints/Lacquers (2024-2032) ($MN)
5 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Ointments & Creams (2024-2032) ($MN)
6 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Laser Therapy Devices (2024-2032) ($MN)
7 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Photodynamic Therapy (PDT) Solutions (2024-2032) ($MN)
8 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Other Product Types (2024-2032) ($MN)
9 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
10 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
11 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Treatment (2024-2032) ($MN)
12 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Drugs (2024-2032) ($MN)
13 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Oral (2024-2032) ($MN)
14 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Topical (2024-2032) ($MN)
15 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Lasers (2024-2032) ($MN)
16 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Phtodynamic Therapy (2024-2032) ($MN)
17 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Other Treatments (2024-2032) ($MN)
18 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
19 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
20 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
21 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
22 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Drug Stores (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
